{"id":"placebo-matching-mitapivat","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL4299940","moleculeType":"Small molecule","molecularWeight":"450.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mitapivat is a small-molecule activator of pyruvate kinase R, the predominant form of pyruvate kinase in red blood cells. By enhancing PKR activity, the drug increases glycolytic ATP production, which strengthens the red blood cell membrane and reduces hemolysis. This mechanism is particularly beneficial in hemolytic anemias where red blood cell survival is compromised.","oneSentence":"Mitapivat activates pyruvate kinase R (PKR), an enzyme that increases ATP production in red blood cells to improve their survival and function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:27:57.214Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pyruvate kinase deficiency"},{"name":"Sickle cell disease"}]},"trialDetails":[{"nctId":"NCT05031780","phase":"PHASE2, PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2022-02-11","conditions":"Sickle Cell Disease","enrollment":286},{"nctId":"NCT05175105","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2022-06-06","conditions":"Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia","enrollment":30},{"nctId":"NCT04770779","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2021-11-30","conditions":"Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia","enrollment":258},{"nctId":"NCT04770753","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2021-12-20","conditions":"Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia","enrollment":194},{"nctId":"NCT05144256","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2022-06-08","conditions":"Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia","enrollment":49},{"nctId":"NCT03548220","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2018-08-09","conditions":"Pyruvate Kinase Deficiency, Anemia, Hemolytic","enrollment":80},{"nctId":"NCT04472832","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2020-06-17","conditions":"Healthy Volunteers","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo Matching Mitapivat","genericName":"Placebo Matching Mitapivat","companyName":"Agios Pharmaceuticals, Inc.","companyId":"agios-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mitapivat activates pyruvate kinase R (PKR), an enzyme that increases ATP production in red blood cells to improve their survival and function. Used for Pyruvate kinase deficiency, Sickle cell disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}